Lineage Cell Therapeutics, Inc. (LCTX)

ASE – Real Time Price. Currency in USD

1.12

-0.01 (-0.45%)

Market open: Aug 12, 2026, 10:14 AM EDT

1.13

+0.01 (0.88%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Revenue

Gross Profit

Operating Income

Net Income

Income Statement
Balance Sheet
Cash Flow

Income Statement (Annual)

Financials in millions USD. Fiscal year is January – December.

Name

2025

2024

2023

2022

Total Revenue

15M

Cost of goods sold

-845K

-943K

-1M

Gross Profit

14M

13M

Operating expenses (excl. COGS)

-35M

-30M

-32M

-36M

Operating Income

-22M

-21M

-25M

-23M

Non-operating income, total

-47M

-3M

Pretax income

-69M

-19M

-23M

-26M

Equity in earnings

Taxes

-541K

Non-controlling/minority interest

-166K

-27K

-7K

80K

After tax other income/expense

Net income before discontinued operations

-64M

-19M

-21M

-26M

Discontinued operations

Net income

-64M

-19M

-21M

-26M

Dilution adjustment

Preferred dividends

Lineage Cell Therapeutics, Inc. (LCTX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Lineage Cell Therapeutics, Inc. (LCTX)

Income Statement (Annual)

Income Statement (Annual)

Search stocks

Lineage Cell Therapeutics, Inc. (LCTX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Lineage Cell Therapeutics, Inc. (LCTX)

Income Statement (Annual)

Income Statement (Annual)